CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

You are here

Products

back to search results

PSMA [MD105R]

Product group: Primary
Monoclonal/ Polyclonal: Monoclonal
Clone: EP192
Host: Rabbit
Isotype: IgG
Application: Immunohistochemistry (IHC)
Application notes: 50-200
Conjugation Type: Unconjugated
Reactivity: Human
General notes: Localization: cytoplasm.
Buffer: citrate pH6.0 or EDTA pH8.0
UNSPSC code: 12352203

Prostate-specific membrane antigen (PSMA), also known as folate hydrolase 1(FOLH1), is a type II transmembrane glycoprotein belonging to the M28 peptidase family. PSMA has two enzymatic activities, one as a prostate-specific integral membrane folate hydrolase and the other as a carboxypeptidase Anti-PSMA labels normal prostate epithelial cells and prostate tumor cells. Although the expression of PSMA in neovasculature of a variety of solid tumors has been reported, PSMA expression is highly restricted to the prostate. It is a useful marker for prostate tumors. In prostate cancer, overexpression of PSMA is correlated with high tumor grade, non-diploid tumors, and advanced tumor stage. It can be used as an effective predictor for tumor progression in prostate cancer (Shipping Cost: €200.00)

PSMA [EP192]

Prostate-specific membrane antigen (PSMA), also known as folate hydrolase 1(FOLH1), is a type II transmembrane glycoprotein belonging to the M28 peptidase family. PSMA has two enzymatic activities, one as a prostate-specific integral membrane folate hydrolase and the other as a carboxypeptidase Anti-PSMA labels normal prostate epithelial cells and prostate tumor cells. Although the expression of PSMA in neovasculature of a variety of solid tumors has been reported, PSMA expression is highly restricted to the prostate. It is a useful marker for prostate tumors. In prostate cancer, overexpression of PSMA is correlated with high tumor grade, non-diploid tumors, and advanced tumor stage. It can be used as an effective predictor for tumor progression in prostate cancer